Why the study?
Cancer patients have a 4-7-fold increased risk of thrombotic complications, and comparing risk assessment models could enable early identification of high-risk ambulatory patients who would benefit from thromboprophylaxis.
Which risk assessment model best predicts venous thromboembolism in ambulatory cancer patients receiving chemotherapy?
Population
230 ambulatory cancer patients with solid malignancy undergoing chemotherapy
Comparison
Khorana vs PROTECHT vs CONKO vs COMPASS-CAT risk scores
Design
Single-center prospective cross-sectional study
Authors
Loading...
Risk model comparisons for cancer-associated VTE remain hypothesis-generating; leaves open optimal tool for guiding thromboprophylaxis.
Which risk assessment model best predicts venous thromboembolism in ambulatory cancer patients receiving chemotherapy?
The Khorana score is the most accurate risk assessment model for predicting venous thromboembolism in ambulatory cancer patients undergoing chemotherapy.
Muthukumar et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: